Muutke küpsiste eelistusi

Tamoxifen Tales: Suggestions for Scientific Survival [Pehme köide]

(Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA)
  • Formaat: Paperback / softback, 312 pages, kõrgus x laius: 235x191 mm, kaal: 610 g, 50 illustrations (20 in full color); Illustrations, unspecified
  • Ilmumisaeg: 20-Jan-2022
  • Kirjastus: Academic Press Inc
  • ISBN-10: 0323996175
  • ISBN-13: 9780323996174
Teised raamatud teemal:
Tamoxifen Tales: Suggestions for Scientific SurvivalSuurem pilt
  • Formaat: Paperback / softback, 312 pages, kõrgus x laius: 235x191 mm, kaal: 610 g, 50 illustrations (20 in full color); Illustrations, unspecified
  • Ilmumisaeg: 20-Jan-2022
  • Kirjastus: Academic Press Inc
  • ISBN-10: 0323996175
  • ISBN-13: 9780323996174
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780323996174.html
Märksõnad:
Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting the lessons learned from this journey that are applicable to the scientific journey of the next generation of scientists. This book provides a manual on the successful mentoring of young scientists including stories describing how training experience shaped careers to become leaders in academia and the pharmaceutical industry. The book documents Professor V. Craig Jordan’s 50-year career in medical sciences that led to the discovery and development of Selective Estrogen Receptor Modulators (SERMs), which became the standard of women’s healthcare around the world. The SERM Raloxifene revolutionized disease treatment by simultaneously preventing breast cancer and osteoporosis. The SERM tamoxifen marked the first targeted therapy in cancer. It provides a unique account of Professor Jordan’s life as a medical scientist, the only individual not in law enforcement trained as a narcotic officer by the Drug Enforcement Administration in America, and an intelligence officer in the Special Air Service (SAS). The book illustrates the versatility of a scientist in the real world with a commitment to serving societies. Tamoxifen Tales: Suggestions for Scientific Survival will be a useful and interesting book for established medical scientists, research mentors, and advanced students wanting to chart a successful and impactful research career.
  • Highlights the lessons learned from the journey behind discovery science, which are applicable to the scientific journey of the next generation of scientists
  • Provides a manual on the successful mentoring of young scientists to become leaders in academia and the pharmaceutical industry
  • Examines cancer treatment based on a personal determination to challenge at the frontiers of the science and to relate to personal life experience
  • Includes references for further research reading

Arvustused

". The story is engaging, the accomplishments remarkable and highly impactful. Dr. Jordan has not only mentored his students and fellows, he has helped support their educational expenses on occasion and has endowed lectureships in former institutions important to his development.

Finally, I am disheartened by one of the early vignettes in this book: Craig recounts his own struggle with metastatic renal cell carcinoma. Four years and all the usual therapies with good but waning results. May the ongoing search for another effective approach bear fruit. V. Craig Jordan still has much to contribute!" --The Cancer Letter

About the author xix
Acknowledgments xxi
The scope and foundation steps in a career xxiii
Foreword xxvii
Melvyn Bragg
Why write this book? xxxi
Prelude xxxix
Chapter 1 Beginnings
1(16)
Going to America
4(3)
My early years in Cheshire
7(4)
Growing up in Bramhall
11(6)
Chapter 2 Leeds University: foundation of a career
17(12)
Postscript on Career Preparation for a Degree in Pharmacy from the Department of Pharmacology at Leeds
25(3)
References
28(1)
Chapter 3 The chance to be a Ph.D. student at the University of Leeds
29(6)
References
33(2)
Chapter 4 Two antiestrogenic strategies to treat breast cancer at the Worcester Foundation
35(12)
Breakthrough
43(1)
Postscript
44(2)
References
46(1)
Chapter 5 A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds
47(20)
Chemoprevention
51(2)
The move to adjuvant therapy
53(4)
Unanticipated sadness and success of Alderley Park
57(1)
An investigation of the molecular mechanism of action of tamoxifen
57(5)
A time of major decisions
62(1)
References
63(4)
Chapter 6 Tamoxifen's patenting problems in America, which created a "cancer treatment company"
67(6)
References
70(3)
Chapter 7 Two opportunities on different continents
73(10)
References
80(3)
Chapter 8 The good, the bad and the ugly of tamoxifen at Wisconsin
83(22)
Animal models---finding the bad about tamoxifen
92(2)
Linking tamoxifen with endometrial cancer
94(6)
References
100(5)
Chapter 9 "Sliding Doors" and serendipity
105(26)
References
129(2)
Chapter 10 South to Northwestern in Chicago
131(24)
The research plan to build a new Tamoxifen team at the Robert H. Lurie Cancer Center
131(3)
Educational outreach and research priorities at the Robert H. Lurie Comprehensive Cancer Center
134(2)
Deciphering the molecular mechanism of antiestrogen action and the new science of estrogen-induced apoptosis
136(2)
Extensive animal models of estrogen-induced apoptosis to decipher pathways and clinical utility
138(1)
Consolidating the financial flow with federal grants
139(1)
Celebrations around the Diana, Princess of Wales Professorship in Cancer Research
140(2)
A surprise honor The glamor of the "Big Three of Cancer Research": Bristol Myers Squibb Award (2001), American Cancer Society Medal of Honor (2002), and the Charles F. Kettering Prize (clinical) from General Motors (2003): a triumph for the Robert H. Lurie
142(2)
Comprehensive Cancer Center at its zenith
144(9)
Conclusion
153(1)
References
153(2)
Chapter 11 Forward to the Fox Chase Cancer Center in Philadelphia
155(8)
The Fox Chase Cancer Center Tamoxifen Team
156(3)
Peer recognition at Fox Chase Cancer Center for the accomplishments of the Tamoxifen Teams
159(2)
References
161(2)
Chapter 12 Get out and go to Georgetown
163(8)
Building my Tamoxifen Team at Georgetown
163(2)
The Peacock Cafe, Georgetown
165(1)
Graduate students at Georgetown
166(1)
References
167(4)
Chapter 13 Closing the circle on Tamoxifen Tales
171(16)
References
184(3)
Chapter 14 "If I wanted to buy your brain, what would that cost?": rebirth at M.D. Anderson Cancer Center
187(8)
Ping Fan completes our molecular mechanism to explain the increase in breast cancers in the CEE/MPA treated women 10 years after menopause in the WHI
188(1)
Philipp Maximov, Balkees Abderrahman, and Ramona Curpan define the molecular mechanism of action of the partial estrogen agonist bisphenol to delay apoptosis
189(1)
Balkees Abderrahman and Ramona Curpan define the molecular mechanism of action of the clinically relevant estrogen mimic TTC-352
190(1)
Battle with the "enemy within" 4 years later
190(1)
Recognition from national academies and major international awards that acknowledge a change in medicine while at the MD Anderson Cancer Center
191(1)
Recognition from professional academic societies
192(1)
Recognition, honorary appointments or honorary degrees, etc.
193(1)
References
193(2)
Chapter 15 "Invest in the young"
195(6)
Chapter 16 Scientific survival suggestions
201(6)
Chapter 17 An account of students obtaining a Ph.D. degree (or an MD for physicians in the British System) while in the Tamoxifen Team over the last 50 years
207(14)
Clive J. Dix, Department of Pharmacology, University of Leeds, 1976--79; ICI Pharmaceuticals Division Research Scholar
208(1)
Anna T. Riegel (Nee Tate), McArdle Laboratory for Cancer Research, University of Wisconsin, 1980--83; Fulbright Hays Scholar
208(1)
Stewart D. Lyman, McArdle Laboratory, University of Wisconsin, 1982--84
209(1)
Ethel M. Cormier, Molecular and Cellular Biology Graduate Program, University of Wisconsin, 1982--88
209(1)
Marco M. Gottardis, Department of Human Oncology, University of Wisconsin, 1983--89
209(1)
Catherine S. Murphy, Department of Human Oncology, University of Wisconsin, 1984--90
210(1)
Meei-Huey Jeng, Department of Human Oncology, University of Wisconsin, 1987--92
210(1)
Shun-Yuan Jiang, Department of Human Oncology, University of Wisconsin, 1987--92; Scholarship from the Taiwanese Ministry of Defense
211(1)
Doug M. Wolf, Department of Human Oncology, University of Wisconsin, 1988--93; Susan G. Komen graduate student
211(1)
John J. Pink, Department of Human Oncology, University of Wisconsin, 1990--95
212(1)
William H. Catherine Department of Human Oncology, University of Wisconsin, MD/Ph.D. program, 1991--95
212(1)
Jennifer I. MacGregor-Schafer, Northwestern University, Department of Defense Graduate Student Training Program, Chicago, IL, 1995--2001
213(1)
Ruth M. O'Regan, University College, Dublin, Ireland, 1996--2000 (Faculty in Medical Oncology, Northwestern University, Chicago, IL)
213(1)
Rita C. Dardes, Department of Obstetrics and Gynecology, University of Sao Paulo, Brazil, 1998--2001
214(1)
Philipp Y. Maximov, N.I. Pirogov Russian National Medical Research University, Russia, 2006--10
215(1)
Ifeyinwa Obiorah, Department of Oncology, V.T. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2010--14
215(1)
Elizabeth Sweeney, Department of Oncology, V.T. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2011--14
216(1)
Balkees Abderrahman, Department of Breast Medical Oncology, University of Texas, MD, Anderson Cancer Center/University of Leeds, split site model C applicants of very high quality (inaugural candidate) 2017--20
216(1)
References
217(4)
Chapter 18 Case studies: in their own words
221(38)
Clive James Dix, Ph.D.
222(1)
Anna Riegel, Ph.D.
223(1)
Marco Gottardis, Ph.D.
224(1)
Survival for the scientist in Big Pharma, biotech, and beyond
224(7)
Andreas Friedl, MD
231(2)
Doug Wolf, Ph.D.
233(3)
Shun-Yuan Jiang, Ph.D.
236(1)
I am proud to be a member of the Tamoxifen Team
236(2)
William H. Catherino, MD, Ph.D.
238(1)
Jordan's Marines
238(2)
Anait S Levenson, MD, Ph.D.
240(1)
Debra A. Tonetti, Ph.D.
241(2)
Rita Dardes, MD, Ph.D.
243(2)
Clodia Osipo, Ph.D.
245(2)
Ruth O'Regan, MD
247(2)
David Bentrem, MD
249(1)
Joan Lewis-Wambi, Ph.D.
250(1)
Lessons learned in the laboratory
250(1)
Serendipitous discovery
251(1)
Philipp Y. Maximov, MD, Ph.D., MBA
252(2)
Ping Fan, MD, Ph.D.
254(1)
Balkees Abderrahman MD, Ph.D.
255(4)
Index 259
V. Craig Jordan is Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer. In 2019 he was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II for services to womens health.